POP Biotechnologies (POP BIO), a biotechnology company specializing in nanoparticle-based vaccines, and the Coalition for Epidemic Preparedness Innovatio...
Everlab, the AI-powered health platform reimagining preventive care, announced a US$10 million (AU$15 million) seed round led by global growth equity fir...
Moderna provided an update on its two planned research and manufacturing facilities at Shonan Health Innovation Park (iPark) in Fujisawa, Kanagawa Prefectu...
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US Cornerstone of investment is...
Ginkgo Bioworks launches cost-effective, high-throughput ADME profiling service to accelerate small molecule drug discovery with model-ready datasets Gi...
BriaCell Therapeutics Corp. a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announc...
Addgene, a purpose-driven organization helping scientists conduct experiments with greater ease, speed, and reproducibility, announced a strategic ...
Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution...
The partnership combines Secarna’s OligoCreator® technology with Vect-Horus’ VECTrans® platform to enable system...
Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech a...
Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced a new collaboration with Merck, known as MSD outside of...
Collaboration to create novel antibody drug candidates using Chugai's proprietary antibody engineering technologies for drug targets identified through...
Asahi Kasei Pharma has started trial drug administration in a Phase III study of ART-123 in Japan (generic name: thrombomodulin alfa; marketed as Recomod...
-JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR) announced that it achieved the enrollment of the target number of participants in the global Phase III cli...
© 2025 Biopharma Boardroom. All Rights Reserved.
